Neil Chanchlani, Simeng Lin, Claire Bewshea, Benjamin Hamilton, Amanda Thomas, Rebecca Smith, Christopher Roberts, Maria Bishara, Rachel Nice, Charlie W Lees, Shaji Sebastian, Peter M Irving, Richard K Russell, Timothy J McDonald, James R Goodhand, Tariq Ahmad, Nicholas A Kennedy
BACKGROUND: We sought to report the effectiveness of infliximab and adalimumab over the first 3 years of treatment and to define the factors that predict anti-TNF treatment failure and the strategies that prevent or mitigate loss of response. METHODS: Personalised Anti-TNF therapy in Crohn's disease (PANTS) is a UK-wide, multicentre, prospective observational cohort study reporting the rates of effectiveness of infliximab and adalimumab in anti-TNF-naive patients with active luminal Crohn's disease aged 6 years and older...
April 16, 2024: Lancet. Gastroenterology & Hepatology